Analysis of 89 Cases of Adverse Reactions Induced by Telmisartan

Abstract

Abstract: Objective To explore the general regulation and characteristics of adverse drug reactions(ADR) induced by telmisartan, and provide reference for clinical rational drug use. Methods 89 cases of telmisartan related ADR were extracted from the adverse drug reaction monitoring and management system for drug adverse reactions in our district from January 2014 to December 2016, and comprehensively analyzed by retrospective classified statistics. Results Among the 89 ADR patients, the incidence of female was higher than that of male, and the age mainly distributed in the range of 61 to 70 years old (40.45％). The mainly involved organs/systems were digestive system (44.92%) and skin and its accessories (25.84%), the main clinical manifestations were nausea, vomiting, abdominal pain, diarrhea, eczema, itching, genital swelling, genital itching, lips swelling, facial edema, eyelid edema, etc. Conclusion Telmisartan has good safety and tolerability, enhance medication monitoring, and reduce ADR occurrence in order to ensure drug safety during clinical application.

Key words: telmisartan, adverse reactions, monitoring, analysis

CLC Number:

R994.11

HAN Bao-xia, QU Hong, GOU Xiao-jun. Analysis of 89 Cases of Adverse Reactions Induced by Telmisartan[J]. Chinese Journal of Pharmacovigilance, 2018, 15(1): 49-51.

References

[1] 范秀珍,郭敌,王华杰.氨氯地平与其联合替米沙坦治疗轻中度高血压的对照研究[J].现代医学,2012,40(1):35.
[2] 唐新明. 离退休干部药物不良反应41例调查分折[J], 海军医学杂志,2012,33(6):403-404.
[3] 赵晓云,路永刚,赵海利,等. 河北省51239体检人群高血压流行病学分析[J].中国老年医学,2013,33(19):4818-4820.
[4] 李军象,颜永平. 替米沙坦联合小剂量吲达帕胺治疗老年原发性高血压的疗效观察[J].中国社区医师,2017,33(6):18-19.
[5] 江彦,傅彦妍,宋洪涛. 我院105例多西紫杉醇不良反应报告分析[J].中国药房,2016,27(26):3646-3649.
[6] 张歆, 秦文明, 翟淑越. 137 例甘露醇注射液不良反应分析[J].中国药物警戒,2016,13(6):364-366.
[7] 龚珊珊,王金明. 国内替米沙坦不良反应文献分析[J]. 药物流行病学杂志,2010,19(6):354-356.
[8] 唐福全. 口服卡托普利致高血钾1例报告[J].锦州医学院学报,2005,26(3):56.
[9] Michel M C,Bohncr H,Koster J,et a1.Safety of telrnisartan in Patients with arterial hypertension:an open-label observational study[J].Drug Saf,2004,27(5):335-344.
[10] 柏瑾,诸骏仁,蔡绳,等.替米沙坦治疗轻中度高血压的临床疗效和安全性-多中心随机对照临床试验[J].中华心血管病杂志,2002,30(12):738-742.
[11] 黄鹤宇,付军. 替米沙坦降压疗效相关单核苷酸多态性的研究进展[J]. 中国老年学杂志,2013,33(1):234-236.
[12] 卫生部.药品不良反应报告和监测管理办法[S/OL].(2011-05-04)[2017-08-01].http://www.sda.gov.cn/WS01/CL0053/62621.html.
[13] 杨华,魏晶,王嘉仡,等. 药品不良反应/事件报告评价方法研究[J]. 中国药物警戒,2009,6(10):581-584.
[14] 陈芳莲,农秋林.苯磺酸左旋氨氯地平片治疗高血压的临床疗效分析[J].临床合理用药杂志,2014,7(11):26-27.
[15] 向春, 汪潭,张顺利. 替米沙坦联合吲达帕胺治疗老年原发性高血压的临床效果探讨[J]. 中外医学研究,2017,15(18):125-126.